Orthocell's Remplir Drives Record Quarterly Revenue Surge on Expanding Hospital Adoption

2 min read | July 04, 2025 03:13 PM AEST | By Team Kalkine Media

Orthocell's Remplir Drives Record Quarterly Revenue Surge on Expanding Hospital Adoption — Image source: Shutterstock

Growing Adoption in Australia

Orthocell has seen a significant uptick in local usage, with more than 206 surgeons now implementing Remplir in over 166 hospitals. The consistent increase in medical uptake highlights strong confidence in the clinical utility and effectiveness of the product. The company credits this momentum to successful commercial execution and a supportive clinical framework in Australia.

Strategic US Expansion Underway

While the revenue for the reported quarter was solely attributed to the Australian market, Orthocell has begun laying the groundwork for expansion in the United States. The first procedure in the US has been successfully completed, signaling the beginning of its international rollout. To support this, the company has built a robust distribution network comprising 14 distributors and over 100 representatives across 21 states.

This infrastructure is expected to facilitate wider product penetration and hospital onboarding, with significant growth potential as clinical acceptance increases in the US.

Positioned for Global Growth

With the foundation firmly established in the domestic market, Orthocell is now aiming to replicate its success internationally. Strategic planning and market learnings from Australia are being applied to the US commercial strategy, setting the stage for sustained global growth.

The company has indicated that future revenue drivers may include increased contribution from US sales, new hospital collaborations, and broader clinical application of Remplir. Additionally, continued adoption in Australia is anticipated to further enhance financial results in the upcoming financial year.

Orthocell is not currently part of the top ASX 100, but its expanding presence and accelerating product uptake position it as a company to watch within the biotech and medical device space.

As the company strengthens its international footprint, eyes will be on future updates regarding US market traction and ongoing revenue performance.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.